Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin. 1985

H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek

Cultures of human peripheral blood leukocytes (PBL) induced with phytohemagglutinin (PHA) and the phorbol ester 12-0-tetradecanoylphorbol 13-acetate (TPA) produced two types of cytotoxic proteins, indistinguishable in the in vitro assay employing murine L 929 cells as targets. One of these proteins had the antigenic and physicochemical properties of lymphotoxin (LT). We have identified the other cytotoxin as tumor necrosis factor (TNF), mainly on the basis of antigenic cross-reactivity demonstrated with antiserum to TNF, and also by its characteristic physicochemical properties and cell source. Unlike LT, PBL-derived TNF did not bind to Concanavalin A-Sepharose or to several other agglutinin-Sepharose columns specific for carbohydrate moieties common in glycoproteins. The molecular weight of native TNF determined by gel filtration was approximately 40,000 while SDS-PAGE revealed a single sharp peak of 16,500 +/- 500. When cultures of monocytes and lymphocytes separated by elutriation were stimulated with PHA and/or TPA, monocytes were the major source of TNF. In contrast, only lymphocytes produced LT. A mixture of antisera to TNF and LF neutralized all cytotoxicity of crude human lymphokine preparations for L 929 cells, suggesting that TNF and LT are either the only, or the major, cytotoxic proteins present in such crude lymphokine preparations demonstrable in this assay.

UI MeSH Term Description Entries
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002845 Chromatography Techniques used to separate mixtures of substances based on differences in the relative affinities of the substances for mobile and stationary phases. A mobile phase (fluid or gas) passes through a column containing a stationary phase of porous solid or liquid coated on a solid support. Usage is both analytical for small amounts and preparative for bulk amounts. Chromatographies
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013755 Tetradecanoylphorbol Acetate A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA. Phorbol Myristate Acetate,12-Myristoyl-13-acetylphorbol,12-O-Tetradecanoyl Phorbol 13-Acetate,Tetradecanoylphorbol Acetate, 4a alpha-Isomer,12 Myristoyl 13 acetylphorbol,12 O Tetradecanoyl Phorbol 13 Acetate,13-Acetate, 12-O-Tetradecanoyl Phorbol,Acetate, Phorbol Myristate,Acetate, Tetradecanoylphorbol,Myristate Acetate, Phorbol,Phorbol 13-Acetate, 12-O-Tetradecanoyl,Tetradecanoylphorbol Acetate, 4a alpha Isomer

Related Publications

H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
June 1987, The Journal of experimental medicine,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
November 1989, Archives of biochemistry and biophysics,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
July 1988, Journal of immunology (Baltimore, Md. : 1950),
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
September 1989, Scandinavian journal of immunology,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
July 1996, Diabetes,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
June 1988, Biochemical and biophysical research communications,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
January 1993, Journal of clinical immunology,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
August 1988, Journal of immunology (Baltimore, Md. : 1950),
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
February 1990, International journal of cancer,
H C Kelker, and J D Oppenheim, and D Stone-Wolff, and D Henriksen-DeStefano, and B B Aggarwal, and H C Stevenson, and J Vilcek
December 1988, Pediatric research,
Copied contents to your clipboard!